Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Landscape Research 2024
22. November 2024 07:10 ET
|
Research and Markets
Dublin, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The "Wet Age-Related Macular Degeneration (Wet AMD) - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. The emergent...
Dry Eye Syndrome Treatment (Evaporative, Aqueous Deficient) Market Trends Analysis Report 2024-2030: New Product Launches, Strategic Initiatives by Key Players, and Innovations Bolster Growth
19. November 2024 11:22 ET
|
Research and Markets
Dublin, Nov. 19, 2024 (GLOBE NEWSWIRE) -- The "Dry Eye Syndrome Treatment Market Size, Share and Trends Analysis Report by Type (Evaporative, Aqueous Deficient), Drug, Product, Dosage Form, Sales...
10 Year 7 MM Glaucoma Epidemiology Forecasts 2023-2033: US, France, Germany, Italy, Spain, the UK, and Japan
18. November 2024 10:40 ET
|
Research and Markets
Dublin, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The "Glaucoma: Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the risk...
Age-Related Macular Degeneration (AMD) Drugs Market Research 2024: Lucentis, Eylea, Eylea HD, Vabysmo, Syfovre, Ranibizumab, Aflibercept, Faricimab, Biologic, Biosimilar - Global Forecast to 2029
08. November 2024 11:26 ET
|
Research and Markets
Dublin, Nov. 08, 2024 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration (AMD) Drugs Market by Product (Lucentis, Eylea & Eylea HD, Vabysmo, Syfovre), Molecule (Ranibizumab, Aflibercept,...
Ophthalmics Market Collaboration and Licensing Agreements Analysis Report 2024: Benchmark Deals with In-Depth Access and Analysis of Financials and Contract Terms
07. November 2024 06:59 ET
|
Research and Markets
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Ophthalmics Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
Ranibizumab (Lucentis) Biosimilars Pipeline Review: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
24. Oktober 2024 09:54 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ranibizumab (Lucentis) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information...
Acute Ocular Pain Market Research Report 2024-2030: Infections, Glaucoma, and Inflammation Fuel Market Growth as New Pharmaceutical Advancements Boost Treatment Options
23. Oktober 2024 07:25 ET
|
Research and Markets
Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "Global Acute Ocular Pain Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by Source of Pain, Treatment Type, Sales Channel,...
Non-Infectious Macular Edema Treatment Research Report 2024-2030: Developments in Nanotechnology and Growing Adoption of Combination Therapies in NIME Expands Opportunities
09. Oktober 2024 04:37 ET
|
Research and Markets
Dublin, Oct. 09, 2024 (GLOBE NEWSWIRE) -- The "Non-Infectious Macular Edema Treatment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global...
Diabetic Macular Edema Treatment Research Report 2024-2030: Market to Grow by $800 Million - Emergence of Novel Therapeutics Strengthens Business Case for Targeted Treatments
01. Oktober 2024 05:25 ET
|
Research and Markets
Dublin, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Macular Edema Treatment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
Evolving Landscape of Open-Angle Glaucoma Pipeline Therapies in 2024
25. September 2024 04:12 ET
|
Research and Markets
Dublin, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The "Open-Angle Glaucoma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.A comprehensive analytical report has been...